PatentVest, Inc.

PatentVest, Inc. is an integrated intellectual property (IP) intelligence, strategy consulting, and law firm headquartered in Addison, Texas. The company's mission is to empower visionary companies to achieve technology leadership by building and protecting transformative technologies.

PatentVest offers an end-to-end IP development platform that includes intelligence gathering, strategic development, invention management, and comprehensive IP legal services. These services encompass patent drafting, U.S. and global filing and prosecution, patent management, trade secret management, and foreign attorney management. The firm leverages expert IP analysts and proprietary global patent databases to provide actionable insights and develop integrated IP, R&D, business, and financing strategies for its clients.

As a division of MDB Capital Holdings (NASDAQ: MDBH), PatentVest has a track record of enabling over 16 companies to evolve into technology leaders, collectively achieving an aggregate market value exceeding $26 billion through its IP Excellence Program. Recent activities include a strategic partnership with Docana, Inc. in August 2025 to advance AI innovation and IP strategy, and a March 2026 announcement of an equity-for-services partnership with Life Seal Vascular. The company also regularly publishes "PatentVest Pulse" reports and legal articles on emerging technology and IP trends, such as AI patenting. Key leadership includes Founder & CEO Chris Marlett and COO Javier Chamorro.

Latest updates

Retatrutide Achieves Bariatric Weight Loss Parity, Sparking IP Battle

Event summary

  • Eli Lilly’s retatrutide achieved 28.7% mean weight loss in April 2026, matching bariatric surgery outcomes.
  • PatentVest’s new report, “The Last 20%: Retatrutide, the Glucagon Paradox, and the Race to Own Surgery-Level Weight Loss Without Surgery,” analyzes the implications.
  • The focus is shifting from drug development to intellectual property control and operational execution around existing IP.
  • Multiple companies, including Novo Nordisk, Pfizer, Hanmi, Innovent, Hengrui, and Sanofi, are actively pursuing related therapies and IP positions.

The big picture

The achievement of surgical-level weight loss through non-surgical means represents a significant disruption to the obesity treatment market, currently dominated by bariatric surgery. PatentVest’s analysis highlights a shift from a race to develop the drug to a battle for control of the underlying intellectual property and the ability to deliver consistent results in a commercial setting. This will likely lead to increased consolidation and strategic acquisitions within the pharmaceutical sector.

What we're watching

IP Litigation
Expect increased patent litigation and cross-licensing activity as companies attempt to navigate the existing IP landscape and secure their own positions.
Clinical Efficacy
The gap between clinical trial results and real-world patient outcomes will be a key differentiator, potentially impacting market share and pricing power.
Operational Execution
The ability to efficiently manufacture and distribute these therapies, while managing supply chain and regulatory hurdles, will be critical for sustained success.
CID: 3542